Clinical Trial: Target-Oriented Strategy of Ultra-Low LDL-C (<1.0 vs. 1.0-1.39 mmol/L) in Extreme-High-Risk ASCVD Patients: Clinical Benefit, Safety and Cost-Effectiveness Assessment

U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07615296) titled 'Target-Oriented Strategy of Ultra-Low LDL-C ( halve statin -> discontinue statin) will be performed if LDL-C drops below 1.0 mmol/L, to maintain LDL-C within 1.0-1.39 mmol/L.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Beijing Anzhen Hospital

Information provided by (Responsible Party): Hai Gao, Beijing Anzhen Hospital

Disclaimer: Curated by HT Syndication....